Fascia that dries out, thickens and presses on the nerves running through it is now being named in peer-reviewed work as a driver of lasting pain and stiffness. This page is that work, laid out in full. Part A gathers what published studies say about the tissue itself: what it is made of, how it reports pain, how it thickens, how it is measured, and what has turned up in named conditions. Part B lists the published research behind each of the nine ingredients in Fascial Release. Every entry carries a label for the kind of evidence it is, a plain summary of what it found, and a link to PubMed or the journal.
Last reviewed 30 September 2026. Every link goes to PubMed or the journal.
Every study on this page carries an evidence label, and the label tells you how much weight that study can hold. A meta-analysis or a randomised controlled trial can show whether something works in people. An imaging or anatomical study can show that a tissue is different in people who have a condition. Lab, animal and review papers can explain a mechanism but cannot prove an effect in patients. All of them are here, because a research picture is assembled from all of them, and labelling each one lets you tell them apart at a glance.
Where the maker of an ingredient paid for the trial that tested it, the notes say so, which is ordinary practice in ingredient research. Where two sound studies disagree with each other, both are listed.
Numbers from several trials pooled into one result. The strongest evidence available, as long as the trials feeding it are sound.
A structured search that gathers and summarises every study on one question, without pooling the numbers.
Participants allocated at random to treatment or control. The benchmark for showing that something works.
A trial in people run without randomisation, or open-label with no placebo arm.
An experiment on volunteers, such as stimulating fascia to test how it reports pain, rather than a treatment trial.
Ultrasound, elastography or MRI measurements comparing fascia in patients against fascia in controls.
Human tissue examined under the microscope or in dissection.
Cell, animal or biochemical work. Shows a mechanism, not an effect in patients.
A handful of patients treated and written up, with no control group.
A narrative summary or hypothesis paper from specialists. Useful for context, not primary evidence.
A paper putting forward definitions or agreed terminology.
Fascia is the connective tissue that fills every gap between everything else in the body. One continuous sheet, wrapped around every muscle, nerve, joint and organ. Until recently it was written off as packing material. The research below, nearly all of it from the last five to ten years, is why that view has changed.
Healthy fascia is soft, supple and mostly water. Hyaluronic acid holds that water in place, made by cells inside the fascia itself and carried in a framework of collagen. As long as water and nutrients keep arriving, the layers stay hydrated and slide freely over the muscles and nerves they wrap. What follows is the anatomy: what fascia is made from, the cells that keep it wet, and how much hyaluronic acid different parts of the body carry.
Who and what was studiedA consensus paper from the fascia nomenclature committee of the Fascia Research Society.
What it foundSets out an agreed definition of the fascial system as one soft connective tissue network running through the whole body, and explains why the field needed one.
Study notesAgreed terminology, not measured data.
Who and what was studiedSix fascia researchers pooling histology, mechanics and clinical findings.
What it foundArgues fascia qualifies as an anatomical system: layered sheets that carry tension and shear against each other, built from one stiff collagen layer type and one viscous layer rich in hyaluronic acid.
Study notesA proposal from a research group, not a trial.
Who and what was studiedNeck, abdominal and thigh fascia from three fresh cadavers, plus ultrasound of 22 volunteers.
What it foundHyaluronan sits between fascia and muscle and inside the loose tissue dividing the fibrous sublayers, alongside cells that look built to make it. Deep fascia measured 1.88 mm at the fascia lata, 1.68 mm at the rectus sheath and 1.73 mm at the sternocleidomastoid.
Study notesThree donors, and the mechanism is proposed rather than tested.
Who and what was studiedHuman fascia examined by staining, immunohistochemistry, electron microscopy and RT-PCR for HAS2.
What it foundNames a distinct cell, the fasciacyte, sitting where fascia meets muscle and between its sublayers, which builds the hyaluronan-rich matrix the layers need in order to glide.
Study notesOne research group; sample size not given in the abstract.
Who and what was studiedHuman fascia sampled from several sites around the body.
What it foundThe first direct measurement of how much hyaluronan human fascia holds, and it tracks how much that fascia has to slide: roughly 35 µg/g in the fascia lata, 29 in the rectus sheath, 6 where fascia sticks to muscle, and about 90 in the ankle retinacula.
Study notesCross-sectional tissue analysis.
Who and what was studiedFascia taken during orthopaedic surgery from eight women aged 42 to 70, plus cultured fascial fibroblasts.
What it foundOestrogen receptor alpha and relaxin receptor 1 turn up in fibroblasts at every fascial site tested, and less so after menopause. Offered as a route from hormones through to myofascial pain.
Study notesTissue from eight women.
Who and what was studiedFibroblasts from human fascia lata dosed in vitro with oestradiol and relaxin-1 at menstrual, menopausal and pregnancy levels.
What it foundFascial cells changed what they built according to the hormone level: collagen-I positivity dropped from 6 percent to 1.9 percent with oestradiol, and further again once relaxin-1 was added.
Study notesCell culture.
Who and what was studiedA short narrative review.
What it foundDescribes fascia as densely nerved and full of vessels, lymphatics and hormone and neurotransmitter receptors, and proposes fascial dysregulation as a thread running through hypermobility, autonomic problems and mast cell activation.
Study notesHypothesis-generating review.
Who and what was studiedThigh fascial layers from three fresh cadavers set against ultrasound of 20 healthy volunteers.
What it foundMaps thigh fascia layer by layer and gives thickness by region, for instance deep fascia at 557 µm on the front and 1112 µm on the side, which sets reference values for reading fascia on ultrasound.
Study notesHealthy volunteers only.
Who and what was studiedA narrative review of hyaluronan biology in fascia.
What it foundReviews hyaluronan as the most plentiful polysaccharide in connective tissue matrix, how readily chemical, mechanical and hormonal change alters it, and the line running from the cells that make it to chronic pain.
Study notesReview; some mechanism inferred from other tissues.
Who and what was studiedA scoping review, with 31 meta-analyses used to set effect-size and sample-size benchmarks.
What it foundPuts movement organisation and chronic pain, especially in older people, at the front of where fascia research is going, and proposes minimum sample sizes and effect-size thresholds for the field.
Study notesMethodological paper.
Who and what was studiedAbdominal superficial fascia from three adult volunteers, stained and examined by electron microscopy.
What it foundMast cells, the cells that release histamine, sit throughout superficial fascia among the collagen, beside the vessels and close to the nerves, at about 20 per square millimetre. Fascia carries its own inflammatory cells.
Study notesThree donors.
Who and what was studiedA systematic review of 17 histological studies of human fascial planes in the chest, abdomen, lower back and legs.
What it foundConfirms the same multi-layered pattern of dense and loose connective tissue across every region, with the nerve and blood supply that makes fascia relevant to pain, and treats it as a biologically active interface rather than packing.
Study notesRegistered systematic review.
Fascia is not packaging. It is wired. Studies in animals and in people show dense nerve networks inside fascia, many of them the kind that register pain, and their number climbs when the tissue is irritated. In experiments on healthy volunteers, stimulating the fascia hurt more, for longer, and across a wider area than stimulating the muscle underneath it. That is how compressed fascia produces pain no scan of muscle, bone or joint ever accounts for.
Who and what was studiedCGRP and substance P nerve endings counted in rat thoracolumbar fascia, with a first look at human specimens.
What it foundThe fascia is densely nerved and its layers differ sharply: the presumed pain-sensing free endings showed up only in the outer layer and the tissue immediately above it.
Study notesCounted in rat tissue and checked in human samples.
Who and what was studiedImmunohistochemistry of rat thoracolumbar fascia, with some human findings alongside.
What it foundFree nerve endings were the only receptive ending present, most of them staining for CGRP and substance P, and inflamed fascia carried more of them than intact fascia did.
Study notesMostly rat tissue.
Who and what was studiedElectrophysiology from spinal dorsal horn neurones in anaesthetised rats.
What it foundSix to fourteen percent of neurones at Th13 to L2 took pain input from the fascia, and after a low back muscle was inflamed that share rose from 4 to 15 percent, with previously silent segments starting to respond.
Study notesAnimal study.
Who and what was studiedThoracolumbar and gluteal fascia from seven adult mice under electron microscopy and immunohistochemistry.
What it foundA dense rhomboid nerve network runs through fascia, far heavier in the thoracolumbar fascia at 9.01 percent of area and 501 branch points per square millimetre than in the gluteal at 2.78 percent and 140.
Study notesMouse study.
Who and what was studiedTwenty-three histological studies published between 2000 and 2021, ten of them in humans.
What it foundAcross the literature fascia shows everything from free nerve endings to Pacini and Ruffini corpuscles, with CGRP and substance P the commonest markers, and the thoracolumbar fascia is the most studied site.
Study notesMixes human and animal histology.
Who and what was studiedTen tissue types from 11 hip surgery patients and two cadavers, stained for Schwann cells.
What it foundSkin was the most nerved tissue at 0.73 percent positive area and tendon the least at 0.07 percent, with superficial fascia at 0.22 to 0.26 percent carried by networks of fine fibres rather than a few large nerves.
Study notesSmall sample, no pain comparison group.
Who and what was studiedAbdominal and thigh superficial fascia from surgical patients, stained for nerve and sympathetic markers.
What it foundSuperficial fascia carries heavy innervation around the vessels, beside fat cells and within the connective tissue itself, in bundles of about 5 µm and 21 µm, roughly a third of it autonomic.
Study notesDescriptive; sample size not stated in the abstract.
Who and what was studiedTwelve healthy volunteers given ultrasound-guided hypertonic saline into erector spinae muscle, the back layer of the thoracolumbar fascia, and the tissue above it.
What it foundInjecting the fascia hurt significantly more over time than injecting muscle or the layer above it, mostly because the pain lasted longer, and it spread further. The words volunteers used pointed to both A and C fibre nociceptors.
Study notesAcute experimental pain in healthy people, not chronic disease.
Who and what was studiedSixteen healthy subjects given 50, 200 and 800 µL of hypertonic saline into fascia and into multifidus in a blinded cross-over.
What it foundFascia injections beat muscle injections on peak pain by 86 percent, lasted longer and covered 65 percent more area, and loading more volume into the muscle did not close the gap.
Study notesAcute experimental model in healthy volunteers.
Who and what was studiedFourteen male volunteers given nerve growth factor into the lumbar erector spinae fascia, then tested over 21 days.
What it foundPressure pain thresholds fell for a week, exercise pain and sensitivity to impact rose, and pain on an acid injection stayed raised for a fortnight, suggesting fascial nociceptors sensitise unusually easily.
Study notesSmall study in healthy men.
Who and what was studiedA perspective paper from the director of the NIH centre for complementary and integrative health.
What it foundNotes that deep epimysium and aponeuroses are now known to carry small-diameter fibres able to send pain signals, especially where inflammation is present, and argues that fascial glide matters for proprioception and myofascial pain.
Study notesPerspective paper.
Who and what was studiedFascia from 31 human donors and 20 rats, with myofibroblast staining and force measurement on isolated rat tissue.
What it foundMyofibroblasts were denser in human lumbar fascia than in the fascia lata or plantar fascia, and isolated fascia contracted in response to TGF-β1, with contraction tracking myofibroblast density at r = 0.83.
Study notesEx vivo tissue; whole-body effects are modelled, not measured.
Who and what was studiedRats with the thoracolumbar fascia inflamed for 12 days against saline controls, recording from spinal neurons.
What it foundOnce the fascia was inflamed, neurons that never took input from it began responding, the share responding to deep tissue rose from 10.8 to 33.3 percent, and many picked up new receptive fields down the leg.
Study notesAnimal study.
Who and what was studiedHistology of inflamed against intact rat thoracolumbar fascia, counting fibre length and free endings layer by layer.
What it foundInflamed fascia grows significantly more substance P positive endings, so pain can rise because there are more pain-sensing endings, not only because the existing ones fire harder.
Study notesAnimal study.
Who and what was studiedRat thoracolumbar fascia stained for CGRP, substance P and TRPV1, with and without induced inflammation.
What it foundPain-fibre density rose significantly in both the inner and outer layers once the fascia was inflamed, and stimulating the nerve roots produced plasma leakage in it, which is functional proof the nociceptors are there.
Study notesAnimal study.
When water and nutrients stop reaching fascia, the hyaluronic acid inside it clumps and the fluid between its layers thickens. The tissue densifies: it stiffens, the layers stop sliding over one another, and it squeezes the muscles and nerves running through it. The pain literature named fascial densification in 2014 for exactly this change, and separated it from fibrosis, which is scarring of the collagen layers themselves. Densification is described as reversible. Below is the evidence for the idea, the physics underneath it, and the observations that support reversing it.
Who and what was studiedA review of deep fascia structure and mechanics.
What it foundThe paper that split the two terms. Densification is a change in the viscosity of the loose tissue inside fascia, tied to diet, exercise and overuse and described as readily reversible. Fibrosis is damage to the fibrous layers themselves, tied to trauma, surgery, diabetes and age.
Study notesThe review that set the definitions.
Who and what was studiedA review of fascia biology and its hyaluronan-rich matrix in myofascial pain syndrome.
What it foundArgues that fascia's part in myofascial pain has been overlooked, and gathers how changes in the hyaluronan matrix, the fibroblasts and the collagen make-up could produce what is seen after trauma.
Study notesNarrative review.
Who and what was studiedA physical chemistry review of hyaluronan solutions in and underneath deep fascia.
What it foundThe physics behind densification. Hyaluronan solutions are thick and non-Newtonian, so shifts in concentration, molecular weight or inflammatory modification change how fascia slides. Immobility raises concentration and viscosity and cuts lubrication.
Study notesPhysical properties, not a patient study.
Who and what was studiedA narrative review of hyaluronan aggregation across the organs.
What it foundHyaluronan aggregation has now been described in liver, eye, lung, kidney, vessel, muscle, fascia and skin, and everywhere it raises matrix viscosity and produces stiffness, with dynamic ultrasound and elastography able to catch it early.
Study notesNarrative review across organs.
Who and what was studiedA narrative review from an independent group at the University of Ljubljana.
What it foundReviews how chronic inflammation, oxidative stress and altered fat metabolism change fascial hyaluronan, restates reversible densification against stubborn fibrosis, and notes hyaluronan treatments already in use for orthopaedic conditions with shared mechanisms.
Study notesObesity-focused review.
Who and what was studiedEighteen rats, twelve with a one-sided sciatic nerve injury, with hyaluronan and collagen measured in muscle and thoracolumbar fascia at six weeks.
What it foundFascial hyaluronan fell on both sides of the body, to 67 and 113 µg/g against 167 in healthy animals, while collagen rose, so a nerve injury changes fascial matrix well away from the injury itself.
Study notesAnimal study with no pain outcome.
Who and what was studiedTwenty patients with one-sided upper limb spasticity after brain injury, given hyaluronidase injections and followed to three to five months.
What it foundBreaking hyaluronan down with an enzyme restored passive movement at every joint and active movement at most within two weeks, held for months, and brought Ashworth scores down without causing weakness.
Study notesOpen-label case series; the authors ask for placebo-controlled trials.
Who and what was studiedTwenty-eight patients with chronic neck pain and 25 healthy subjects, fascial thickness measured on ultrasound before and after treatment.
What it foundPatient fascia was significantly thicker, and after treatment both pain and thickness came down, with the reduction coming from the loose sublayer rather than the dense one. Proposes 0.15 cm at the sternocleidomastoid as a cut-off.
Study notesSmall trial.
Who and what was studiedOne 40-year-old man with subacute calf pain, imaged before and after manual therapy.
What it foundUltrasound and elastography picked up altered glide, echogenicity and elasticity in the deep fascia, and the change after treatment, as a proof of concept that imaging can show what hands feel.
Study notesSingle case.
Who and what was studiedA scoping review of 11 studies, eight human and three animal, on how fascia manipulation works.
What it foundIn people, manual work cut unbound water in deep fascia and set off a brief local inflammatory response; in animals it damped cytokines through adenosine receptors. Pain from densification eased and neuromuscular effects ran up to a week.
Study notesScoping review.
Who and what was studiedA narrative review pulling hyaluronan biology together across tissue types.
What it foundCasts fascia as a hyaluronan-rich interface that reads inflammatory signals, and lays out the loop in which loading, cytokines, available energy and clearance together set hyaluronan turnover, hydration and viscosity.
Study notesNarrative review.
Who and what was studiedA rabbit thoracolumbar fascia model, with hyaluronan of different molecular weights injected under ultrasound and rheology, tribology and gene expression measured.
What it foundNames hyaluronan as central to densification of the thoracolumbar fascia, and shows that adding it between the layers improved lubrication and glide without setting off fibrosis.
Study notesAnimal model.
Who and what was studiedAdults with painful regions, densifications found by palpation and measured on diagnostic ultrasound before and after a short manual intervention.
What it foundDensified fascia could be found by hand and measured on ultrasound, its thickness tracked pain intensity, and a brief intervention brought both the thickness and the pain down.
Study notesPilot study.
This is where the model meets the tape measure. Ultrasound and elastography can now put numbers on fascial thickness, stiffness, density and how far neighbouring layers move, and the numbers repeat. Fascia that X-ray and MRI never showed is now something researchers can see and count. The lower back is the best studied case: a 2026 pooled analysis of fourteen imaging studies found the fascia thicker, stiffer and denser in people with chronic pain than in people without, with thickening tracking pain. Studies disagree on exactly how layer movement changes, and both sides are listed here.
Who and what was studiedFourteen ultrasound and MRI studies of moderate to high quality comparing thoracolumbar fascia in low back pain patients against people with no symptoms.
What it foundPatient fascia came out thicker (SMD 0.64, 95% CI 0.41 to 0.88, across 12 studies), stiffer (SMD 0.82, 3 studies) and more echogenic (SMD 0.43, 3 studies). No pooled figure for glide between layers, because the two studies on it pointed opposite ways.
Study notesPooled from cross-sectional imaging studies.
Who and what was studiedFourteen studies and roughly 880 participants using quantitative ultrasound markers of the thoracolumbar fascia in non-specific low back pain.
What it foundSeveral studies reported thicker fascia, altered echogenicity or microstructure, and stiffness differences in chronic low back pain. Stiffness varied by elastography method, and shear strain split, with acute studies mostly reporting less deformation and chronic studies reporting either less or more.
Study notesNarrative synthesis of 14 studies.
Who and what was studiedA systematic review of ultrasound studies of the thoracolumbar fascia up to April 2024.
What it foundGathers what ultrasound can now measure in fascia, namely thickness, echogenicity, stiffness, deformation, shear strain and displacement, along with the protocols used for diagnosis, monitoring treatment and tracking change with movement.
Study notesThe authors are reviewing a literature that includes their own work.
Who and what was studiedA pictorial review of ultrasound findings across common fascial lesions.
What it foundPresents ultrasound as a multiparametric tool for thickness, echogenicity, stiffness, deformation and shear strain, able to pick up fascial pathology that a physical examination misses.
Study notesPictorial review with no patient against control data.
Who and what was studiedA cadaveric study of ultrasound-guided needle biopsy of the thoracolumbar, fascia lata and crural fascia, confirmed on histology.
What it foundThe needle landed correctly 91.9 percent of the time on the long axis and 96.2 percent on the short, with no meaningful difference between approaches, which opens the door to studying fascial pathology in living patients.
Study notesCadaveric, not yet validated in living patients.
Who and what was studiedOne hundred and seven adults, 60 with chronic or recurrent low back pain lasting over a year and 47 without, matched on age, sex, BMI and activity.
What it foundThe first quantitative report that connective tissue structure is abnormal in low back pain. The pain group carried around 25 percent more perimuscular connective tissue thickness and echogenicity than controls. That tissue is the fascia around the back muscles.
Study notesCross-sectional, so it cannot show cause.
Who and what was studiedOne hundred and twenty-one adults, 71 with low back pain lasting over a year and 50 without, imaged during passive trunk flexion.
What it foundShear strain between fascial layers was lower in the pain group, 56.4 percent against 70.2 percent, about a fifth less. This is the main source of the finding that fascial layers move less in chronic low back pain.
Study notesA 2025 study using a different method found the change running the other way. Both are listed here.
Who and what was studiedNinety-two subjects, 46 with chronic non-specific low back pain and 46 healthy, fascia measured at L3 on both axes.
What it foundFascia was significantly thicker in the pain group on both axes. Healthy subjects showed a difference between the two axes that patients did not, which the authors read as fascia thickening evenly and losing its adaptability.
Study notesSingle centre, cross-sectional.
Who and what was studiedOne hundred and thirty-one subjects, 68 with chronic non-specific low back pain and 63 without, strain imaging at L2 to L3 and L4 to L5.
What it foundThe pain group's fascial elastic modulus ran 25 to 30 percent lower than healthy individuals, and pain severity tracked the elasticity coefficient strongly in the negative direction (r = -0.76). Age, BMI and sex were unrelated.
Study notesCross-sectional, and the first study of this coefficient in the thoracolumbar fascia.
Who and what was studiedThirty-two patients with chronic non-specific low back pain randomised to four sessions of myofascial release, either on the lower back or on the fascia of the legs.
What it foundPain and the elastic coefficient of lumbar myofascial tissue both changed significantly in both groups, with no real difference between treating locally and treating at a distance.
Study notesSmall, and there was no untreated control group.
Who and what was studiedThirty-two participants with non-specific low back pain and 32 controls, shear strain and thickness measured before and after a standardised massage.
What it foundMovement between the layers was measurably different in the pain group on both cumulated and maximum shear strain, and the elastography figures tracked pain and disability.
Study notesA different measurement method from the 2011 study, and the groups differed in age.
Who and what was studiedThirty patients with chronic non-specific low back pain and 32 healthy controls, all in their late twenties, shear-wave elastography of fascia and the muscles beneath.
What it foundThoracolumbar fascia shear modulus was significantly higher at L4 to L5 on both sides in the pain group, along with stiffer erector spinae and multifidus underneath.
Study notesYoung sample, cross-sectional.
Who and what was studiedFifteen patients with neck and low back pain together and 15 healthy controls, given repeated shear-wave elastography of cervical and lumbar fascia.
What it foundRepeat measurement of fascia stiffness was excellent (ICC at or above 0.90) and thickness good to excellent (ICC at or above 0.80), so the measurement holds up. Patients had significantly thicker lumbar fascia.
Study notesSmall comparison group; mainly a reliability study.
Who and what was studiedSeventy participants with low back pain, ultrasound thickness of the thoracolumbar fascia and the tissue between the abdominal wall muscles, alongside physical tests and questionnaires.
What it foundDocuments that chronic low back pain comes with remodelled lumbar soft tissue, thoracolumbar fascia and perimuscular connective tissue included, and works through which clinical measures those imaging findings line up with.
Study notesExploratory, with no healthy control group.
Who and what was studiedTwenty-one healthy adults for reliability and 15 for comparison, fascial thickness measured by a blinded assessor at restricted sites against the normal opposite side.
What it foundThe measurement was reliable, and fascia was significantly thicker where restriction was found by hand than at the same spot on the unaffected side. What a trained hand reads as densified shows up as thicker on imaging.
Study notesHealthy volunteers.
If fascia can generate pain signals, and if it can be measured as densified in people who hurt, the next question is what happens when the fascia itself is treated. These are the general studies: reviews that put fascia at the centre of chronic pain and stiffness, and trials in which acting on it directly, separating its layers with fluid, numbing it, or releasing it by hand, brought pain down. The condition-by-condition evidence follows in the next section.
Who and what was studiedA state-of-the-art review from McGill and Sherbrooke, independent of the groups that proposed the densification model.
What it foundNames five main deep fascia pathologies: chronic low back pain, chronic neck pain, Dupuytren's disease, plantar fasciitis and iliotibial band syndrome. Across all of them the fascia is stiffer, its myofibroblasts and matrix are altered, its pain fibres are denser and sensitised, and inflammatory markers are present.
Study notesNarrative review.
Who and what was studiedA conceptual review of anatomical, histological, imaging, biomechanical and clinical work published between 2000 and 2025.
What it foundConcludes fascia is richly supplied with nociceptors and sympathetic fibres and changes pathologically in myofascial pain, with imaging and histology showing fibrosis, densification and inflammatory activity. Puts impaired glide, abnormal mechanotransduction and neuroinflammatory sensitisation forward as the routes to pain.
Study notesSingle-author conceptual review.
Who and what was studiedA scoping review of 799 records across MEDLINE, EMBASE, Cochrane, PEDro and medRxiv.
What it foundFinds fascia can shift its biomechanical and physical properties reversibly, that myofibroblasts help hold myofascial tension, and that movement and mechanical work both treat and prevent myofascial pain while sitting still predisposes to it. Proposes a mechanical route from myofascial pain into fibromyalgia.
Study notesInterpretive, and the model is proposed rather than tested.
Who and what was studiedA literature search from 2010 to February 2024 covering trials, observational studies and case reports of fascial plane blocks in chronic pain.
What it foundEvidence is growing for fascial plane blocks in persistent post-surgical, neuropathic, musculoskeletal and cancer pain, though still mostly case reports and series, and the blocks are widening their role alongside or instead of conventional drugs.
Study notesMostly low-level primary evidence.
Who and what was studiedForty-one patients with upper trapezius myofascial pain randomised to saline hydrodissection of the fascial plane or a lidocaine trigger point injection, followed for 12 weeks.
What it foundPain fell significantly with both, hydrodissection at r = 0.716 and the injection at r = 0.604, with comparable gains in McGill pain scores and neck disability and no adverse events. Separating the fascial layers with fluid matched an anaesthetic injection.
Study notesSmall and single-blind.
Who and what was studiedThree patients with cervical myofascial pain that had not responded to first-line conservative care.
What it foundDescribes hydrodissection of the cervical superficial fascia under ultrasound, and puts that layer, with its plexiform nerve network, forward as a pain generator and treatment target in chronic neck pain, cervicogenic dizziness and non-dermatomal paraesthesia.
Study notesThree patients, no control.
Who and what was studiedTwenty-four subjects with chronic non-specific low back pain randomised to guideline physiotherapy with or without fascial manipulation, eight treatments across four weeks with follow-up at one and three months.
What it foundThe group that got fascial work improved significantly on pain, function and wellbeing at the end of care, and on pain in the medium term, against physiotherapy alone.
Study notesSmall trial.
Who and what was studiedA narrative review of the histological, experimental and imaging evidence on the lumbodorsal fascia.
What it foundPulls together that the fascia holds pain-sensing free nerve endings which change shape in chronic pain, that stimulating it in living people raises spinal neuron excitability, and that microinjury or inflammation in the fascia could be driving that sensitisation.
Study notesNarrative review.
Who and what was studiedA PRISMA-based integrative review of human, translational and animal work on myofascial pain up to February 2026.
What it foundDraws trigger-point biochemistry, fascial dysfunction, stress hormones, autonomic imbalance and altered pain processing into one account of why myofascial pain persists and returns, and why a muscle-only model cannot explain it.
Study notesScreened by a single reviewer.
Who and what was studiedEight randomised controlled trials and 375 patients of myofascial release for chronic low back pain.
What it foundWorking on the fascia significantly reduced pain (SMD -0.37) and improved physical function (SMD -0.43) against controls.
Study notesThe pooled effect sizes are moderate.
Who and what was studiedTen randomised controlled trials and 549 participants, rated good to excellent on methodological quality.
What it foundMyofascial release significantly reduced pain and improved neck rotation and side-bending against other treatments.
Study notesThe authors describe the effects as modest.
For each condition below, the studies listed either measured or examined fascia in people who have it, or treated the fascia and recorded what happened. The count beside each name is the total evidence for that condition, cross references included, so it can run ahead of the number of rows shown.
Two 2025 imaging studies found the tissue around the trapezius measurably altered and stiffer in fibromyalgia, with stiffness tracking pain. Biopsy work going back to 1990 had already found the connective tissue matrix changed. Pooled trials show that treating the fascia relieves the pain.
Who and what was studiedA hypothesis paper.
What it foundPuts fascial inflammation forward as the steady peripheral input that drives central sensitisation in fibromyalgia, citing biopsies that found extra collagen and inflammatory mediators in the connective tissue around muscle cells, and fibroblasts releasing IL-6 under strain.
Study notesHypothesis paper.
Who and what was studiedA hypothesis paper setting newer immune findings against known myofascial pathology.
What it foundNotes that fibromyalgia fascial biopsies carry raised inflammatory and oxidative stress markers and extra endomysial collagen, alongside poor muscle relaxation and raised intramuscular pressure, and proposes sympathetic overdrive, poor tissue healing and autoantibodies all converging on myofascial tissue.
Study notesHypothesis paper.
Who and what was studiedThirty-four women with fibromyalgia and 34 healthy controls, quantitative B-mode ultrasound of the upper trapezius and the myofascial tissue around it against pain and symptom scores.
What it foundTissue texture was significantly altered and echointensity raised in the fibromyalgia group, and pain scores predicted how far it had changed. The first imaging study to reliably show measurable tissue change in a condition long said to have nothing to see.
Study notesMeasures the trapezius with its surrounding myofascial tissue, not an isolated fascial layer.
Who and what was studiedEighty-nine women with fibromyalgia and 36 healthy controls, B-mode ultrasound and compression sonoelastography of the trapezius region, skin and subcutaneous tissue.
What it foundThe trapezius region was thicker and measurably stiffer in fibromyalgia, and stiffness tracked pain strongly (r = 0.661). Skin was thinner in patients. Stiffer myofascial tissue, more pain, measured rather than argued.
Study notesElastography of the trapezius and the tissue around it.
Who and what was studiedSkin biopsies from 25 fibromyalgia patients, 5 healthy controls, 8 with rheumatoid arthritis and 9 with local pain after whiplash, stained for IgG and collagen with mast cells counted.
What it foundFibromyalgia biopsies carried significantly more IgG in the dermis and vessel walls, more collagen III reactivity and more mast cells, with degranulation tracking the IgG score. The dermis is connective tissue continuous with the superficial fascia below it.
Study notesSmall biopsy study.
Who and what was studiedSkin biopsies from people with primary fibromyalgia, healthy controls, and patients with lupus and rheumatoid arthritis.
What it foundIgG sat on the collagen bundles and matrix in fibromyalgia skin and not in controls, which the authors read as a change in the quality of the connective tissue matrix itself. Published decades before fascia was on the research agenda.
Study notesEarly biopsy study.
Who and what was studiedSix trials and 279 fibromyalgia patients given myofascial release alone or alongside exercise.
What it foundWorking on the fascia had a large effect on fibromyalgia pain straight after treatment (SMD -0.81) and a moderate one still at six months (SMD -0.61), with sleep and quality of life improved too.
Study notesThe authors call for more high-quality trials.
Who and what was studiedTen studies comparing connective tissue massage, therapist-applied myofascial release and self-myofascial release in fibromyalgia.
What it foundMyofascial release significantly reduced pain with a large effect (SMD -1.16) while general connective tissue massage did not, and the paper treats muscle fascia dysfunction as contributing to fibromyalgia and to central sensitisation.
Study notesThe trials pooled here vary a good deal.
Who and what was studiedTen controlled trials of massage in fibromyalgia published between 1990 and 2013.
What it foundOf every manual approach compared, myofascial release had large effects on pain and medium effects on anxiety and depression, held pain relief in the medium term, and improved fatigue, stiffness and quality of life. Swedish massage, which does not target fascia, did not.
Study notesPooled from 145 participants.
Who and what was studiedEight studies and 222 fibromyalgia patients assessed by skin biopsy or corneal microscopy.
What it foundPooled prevalence of small nerve fibre pathology in fibromyalgia came out at 49 percent, with the authors proposing a role for the peripheral nervous system. These are the fibres that run through fascia and are wired into it.
Study notesModerate heterogeneity.
Who and what was studiedSeventeen women with chronic widespread pain including fibromyalgia and 24 pain-free women, with microdialysis sampling the fluid inside the trapezius tissue.
What it foundThe fluid bathing the tissue between muscle and fascia carried significantly more lactate and glutamate in chronic widespread pain, and it was the tissue concentrations rather than the blood levels that tracked pain thresholds.
Study notesSmall study.
Recent reviews put fascia at the centre of myofascial pain, and a 2025 randomised trial found that separating the fascial layers with fluid worked as well as an anaesthetic injection.
Who and what was studiedThirty-one patients with trapezius myofascial pain syndrome and 31 volunteers, shear-wave elastography across 123 trapezius muscles.
What it foundThickness and blood flow were no different, but shear-wave velocity, the stiffness measure, was significantly higher in the pain group. In myofascial pain the tissue is not thicker, it is stiffer.
Study notesMeasured in the trapezius and its fascia together.
Imaging shows thicker fascia and far less movement between fascial layers in Ehlers-Danlos syndrome, and cultured cells from these patients have switched into the contractile, matrix-degrading state that drives fascial tension.
Who and what was studiedSixty-five people examined prospectively, 26 with hEDS and 39 with chronic neck, knee or back pain without it, using ultrasound and strain elastography at three sites.
What it foundDeep fascia at the sternocleidomastoid was thicker in the hEDS group. Iliac fascia and iliotibial tract thickness did not differ. Elastography suggested that in myofascial pain fascia softens relative to muscle, a shift that was milder in hEDS.
Study notesThe comparison group had chronic pain without hEDS.
Who and what was studiedNine subjects split across hEDS, lower-limb pain without hEDS, and pain-free controls, with ultrasound tissue displacement of the iliotibial tract.
What it foundShear strain came out at 46.2 percent in hEDS against 89.5 percent in lower-limb pain without it and 121.1 percent in pain-free controls, so matrix changes in hEDS may read as less movement between fascial planes.
Study notesA pilot with nine subjects.
Who and what was studiedA narrative review of molecular, histological and biomechanical findings.
What it foundReports consistent abnormalities in fascial thickness, movement between layers, myofibroblast activation, tendon elongation and tissue stiffness across these disorders, and argues hEDS and hypermobility spectrum disorder are better framed as disorders of pathological fascial remodelling.
Study notesReview.
Who and what was studiedThirty-seven people with Ehlers-Danlos syndrome, 23 of them with spondyloarthritis alongside it, imaged with ultrasound and strain elastography.
What it foundThoracolumbar fascia was thickened in both groups and more so where inflammatory arthritis was also present, 5.6 mm against 4.4 mm, so fascial remodelling appears to carry both inflammatory and mechanical processes.
Study notesNo non-EDS control group in this study.
Who and what was studiedCultured skin fibroblasts from hEDS and hypermobility spectrum disorder patients.
What it foundConnective tissue cells from these patients showed matrix components in disarray and had switched into a contractile myofibroblast-like state, with genes for connective tissue upkeep, inflammation and pain all dysregulated. That is the same cell change that drives fascial tension.
Study notesCell culture study.
Who and what was studiedGene expression profiling of hEDS and hypermobility spectrum disorder skin fibroblasts by RNA sequencing, qPCR and immunofluorescence.
What it foundBoth share matrix disarray, myofibroblast differentiation and dysregulated growth factors, structural components and matrix-modifying enzymes, which the authors frame as a cycle of matrix breakdown and inflammation running through the whole connective tissue system. These are the cells that build and maintain fascia.
Study notesA cell study, supporting the pathway rather than measuring patient tissue.
Who and what was studiedTwenty-one people with hypermobility spectrum disorder and 22 controls, strain elastography of five muscles and two tendons.
What it foundStrain index was significantly lower in the hypermobility group at the brachioradialis, patellar tendon and Achilles, with more soft-tissue signal in the biceps and Achilles. Direct imaging evidence that connective tissue properties differ measurably in hypermobility.
Study notesExploratory cross-sectional study.
Who and what was studiedTwenty women with hEDS and 20 matched controls, tested on pressure pain thresholds, temporal summation, conditioned pain modulation and exercise-induced pain relief.
What it foundThe hEDS group had lower pressure pain thresholds, significantly more temporal summation under repeated pressure, and less pain relief from exercise at the quadriceps, which is the pattern a sustained input from a sensitised tissue produces.
Study notesSmall experimental study.
Who and what was studiedThree hundred and eighteen women diagnosed with chronic myofascial pelvic pain at a tertiary centre, 77 of them with generalised hypermobility spectrum disorder.
What it foundTwenty-four percent of the women with chronic myofascial pain met criteria for generalised hypermobility spectrum disorder, well above the general population, with hypermobility carrying 7.5 times the odds of low back pain and three times the odds of hip pain.
Study notesRetrospective chart review.
POTS is now firmly tied to connective tissue disorders. Cohort after cohort finds roughly a third of patients meeting full hEDS criteria and more than half carrying some degree of hypermobility, which is exactly where fascia has been measured as thicker and less mobile.
Who and what was studiedNinety-one POTS patients assessed against the 2017 hEDS diagnostic checklist.
What it foundThirty-one percent met full clinical criteria for hEDS and another 24 percent had generalised joint hypermobility short of full criteria, so more than half carried a connective tissue disorder. hEDS is the condition in which fascia has been measured as thicker and less mobile.
Study notesSingle-centre cohort.
Who and what was studiedThree hundred and sixty-two children and adolescents with POTS assessed for Ehlers-Danlos syndrome and hypermobility spectrum disorder.
What it foundTwenty-three percent had Ehlers-Danlos syndrome and another 39 percent had hypermobility spectrum disorder, so roughly six in ten young POTS patients carried a diagnosable connective tissue disorder, and those with EDS started younger.
Study notesLarge clinic series.
Who and what was studiedRecords of 392 patients with orthostatic intolerance, 100 of them meeting POTS criteria, reviewed for joint hypermobility and mast cell activation.
What it foundBetween 13 and 34 percent had a joint hypermobility disorder depending on the definition used, and up to 87 percent met clinical criteria for mast cell activation, with patients responding to therapy however strictly they were defined.
Study notesRetrospective review.
Between 15 and 45 percent of people with Sjögren's meet full criteria for fibromyalgia, and that widespread pain does not track the inflammatory markers, which is the signature of a myofascial source rather than the autoimmune process.
Who and what was studiedOne hundred consecutive primary Sjögren's patients assessed for fibromyalgia by 2010 ACR criteria, with disease activity and patient-reported indices.
What it foundThirty-one percent met criteria for fibromyalgia, and widespread pain and symptom severity tracked the Sjögren's patient-reported index closely (r = 0.65 and 0.72). Close to a third carry the widespread myofascial pain pattern.
Study notesCross-sectional study.
Who and what was studiedFour hundred and thirty-seven primary Sjögren's patients from the national SJOGRENSER registry.
What it foundFourteen point six percent had fibromyalgia, and those patients carried significantly more fatigue, joint pain and constitutional symptoms with higher activity scores, yet no difference in laboratory or histological inflammation. The pain burden does not follow the inflammatory markers.
Study notesRegistry study.
Who and what was studiedNinety-seven consecutive primary Sjögren's patients given fibromyalgia questionnaires, nerve conduction studies, EMG and MRI.
What it foundForty-five percent met diagnostic criteria for fibromyalgia, and it did not line up with polyneuropathy, myopathy or laboratory findings, so the authors treat it as a comorbidity needing its own approach rather than a feature of the autoimmune disease.
Study notesSingle-centre study.
Who and what was studiedNinety-two patients seen in a Sjögren's clinic, classified on objective criteria and screened for widespread pain by the 1990 ACR definition.
What it foundLooks at how far widespread pain, the defining feature of fibromyalgia, runs alongside Sjögren's in a clinic population classified objectively, and documents it as a feature of the condition rather than a coincidence.
Study notesClinic-based study.
Cartilage and bone do not explain osteoarthritis pain: across ten years and nearly 5,000 patients, imaging accounted for under a third of symptoms. The connective tissue around the joint is where researchers are now looking, and it stiffens, turns fibrotic and loses its lubrication.
Who and what was studiedKnee osteoarthritis surgery patients split by how long they had had the disease, against healthy controls, with plantar fascia thickness on ultrasound.
What it foundPlantar fascia was thicker in knee osteoarthritis than in controls, 0.44 and 0.42 cm in long-standing disease and 0.37 and 0.34 cm in recent disease against 0.30 cm in controls, so fascial change travels with the condition even at a distance from the knee.
Study notesMeasured at the plantar fascia, well away from the knee.
Who and what was studiedOne hundred and thirteen people with knee osteoarthritis grouped by pain level and X-ray grade, with quantitative sensory testing.
What it foundPain and X-ray damage did not line up: 30 had high pain on low damage and 27 low pain on high damage. The high-pain, low-damage group was more pain sensitive, which is the pattern a persistent input from soft tissue around the joint produces.
Study notesCross-sectional.
Who and what was studiedFour thousand seven hundred and ninety-six knee osteoarthritis patients followed for ten years, with 24,256 X-ray readings and 2,851 MRI scores modelled against symptoms.
What it foundNeither X-ray features nor MRI scores predicted pain, explaining only 15 to 28 percent of symptoms, and prediction got worse the worse the symptoms were. If bone and cartilage explain that little, the rest has to come from the soft tissue around the joint.
Study notesLarge registry analysis.
Who and what was studiedA review of what drives fibrosis of the connective tissue lining the joint in osteoarthritis.
What it foundReports synovial fibrosis as a frequent finding in osteoarthritis and a heavy contributor to pain and stiffness, and walks through the drivers including TGF-β, connective tissue growth factor and hyaluronan. The synovium is connective tissue continuous with the fascia around the joint.
Study notesNarrative review.
Who and what was studiedA review of the connective tissue and fat structure inside the knee capsule in osteoarthritis.
What it foundTreats the infrapatellar fat pad as an active contributor through inflammatory mediators that keep inflammation, fibrotic remodelling and neurogenic pain going, with preclinical work suggesting that calming it relieves pain. The pad sits inside the fibrous capsule, threaded with connective tissue and nerves.
Study notesNarrative review.
Who and what was studiedA review of the infrapatellar fat pad in knee osteoarthritis.
What it foundThe pad sits between capsule and synovial membrane, carries a rich nerve supply, and in knee osteoarthritis its inflammation, growth and fibrosis may be a pain source. A richly nerved connective tissue structure turning fibrotic and painful is the fascial mechanism at joint level.
Study notesNarrative review.
Who and what was studiedSixty-six women over 50 with medial knee osteoarthritis, shear-wave elastography of the posterior capsule, ligament and surrounding muscles.
What it foundStiffness of the medial posterior capsule was significantly linked to how far the knee could straighten. The connective tissue around the joint limits movement, not only the joint itself, and that capsule is continuous with the fascia of the leg.
Study notesCross-sectional.
Who and what was studiedThirteen low-risk-of-bias studies, six observational and seven experimental, on myofascial pain and trigger points in hip and knee osteoarthritis.
What it foundActive myofascial trigger points showed up more in the quadriceps and hamstrings of knee osteoarthritis patients than in healthy people, and treating the myofascial tissue improved pain and function at both hip and knee against sham.
Study notesScoping review.
Who and what was studiedOne hundred and fourteen patients with painful knee osteoarthritis examined for myofascial trigger points across six muscle groups.
What it foundTrigger points were common in every group examined, reaching 50 percent in the tensor fasciae latae, and how many a patient had tracked their pain and disability.
Study notesSecondary analysis.
Who and what was studiedA critical review of observational and interventional work on myofascial pain in osteoarthritis.
What it foundArgues that the familiar mismatch between osteoarthritis pain and X-ray findings is partly pain coming from the myofascial tissue around the joint, and finds early evidence that trigger points contribute to pain and disability at the knee.
Study notesNarrative review.
Who and what was studiedA review of the connective tissue cell changes in the joint lining in osteoarthritis.
What it foundFibrosis of the joint lining drives the disease forward: its fibroblasts convert into contractile myofibroblasts, lay down excess matrix and stiffen the capsule, feeding chronic inflammation, nerve sensitisation and joint dysfunction. The same cell change that densifies fascia.
Study notesNarrative review.
Who and what was studiedEx vivo and in vitro models of the joint lining held under stiff, fibrotic conditions.
What it foundA stiff environment pushed the lining's fibroblasts into a fibrotic state that made less lubricant, and blocking their contractility restored it. Stiffening and loss of lubrication feed each other, which is the relationship that defines densification.
Study notesLaboratory study.
Every nerve travels through fascia. In carpal tunnel syndrome the tissue around the nerve is measurably thicker and twice as stiff, and in diabetes a thickened plantar fascia predicted neuropathy years before it arrived.
Who and what was studiedCarpal tunnel syndrome patients and healthy controls, ultrasound of the connective tissue around the flexor tendons at three levels of the tunnel.
What it foundThe tissue wrapping the tendons was thicker in patients at all three levels, 0.60 to 0.63 mm against 0.46 to 0.50 mm. Non-inflammatory fibrosis of this sheath is a major finding in idiopathic carpal tunnel syndrome, so the nerve is squeezed by thickened connective tissue rather than bone.
Study notesThe layer measured is the peritendinous sheath inside the tunnel.
Who and what was studiedSeven studies measuring subsynovial connective tissue thickness in people with and without carpal tunnel syndrome.
What it foundAll four case-control studies found the tissue significantly thicker in carpal tunnel syndrome, and the thickening may arrive before electrodiagnostic tests change, so measuring it could catch the condition early.
Study notesQualitative synthesis only.
Who and what was studiedDissection of 11 feet, histology of 10 surgical neuromas, and MRI of 40 patients against 29 controls.
What it foundThe common digital plantar nerve runs inside concentric layers of fibrous and loose connective tissue continuous with the deep foot fascia, and on MRI dorsal fascia thickness was the only measure that separated patients from controls.
Study notesA foot-specific entrapment.
Who and what was studiedThirty-seven carpal tunnel patients across 60 wrists and 18 healthy volunteers across 36, with shear-wave elastography of the median nerve.
What it foundThe nerve and its sheath were twice as stiff in carpal tunnel syndrome, 66.7 kPa against 32.0, and stiffer again in severe cases at 101.4 kPa, with a cut-off diagnosing the condition at 93 percent sensitivity.
Study notesCross-sectional.
Who and what was studiedFifty-eight carpal tunnel patients across 79 wrists and 55 healthy controls across 63.
What it foundNerve stiffness was significantly higher in carpal tunnel syndrome, 19.4 against 11.1 kPa, and climbed with severity to 22.4 kPa. The tissue around a compressed nerve stiffens measurably, and the stiffness tracks the damage.
Study notesCross-sectional.
Who and what was studiedThree hundred and forty-four adolescents with type 1 diabetes, plantar fascia thickness measured at baseline then complications tracked over a median 3.2 years.
What it foundThickened plantar fascia at baseline, found in 38 percent, predicted later peripheral neuropathy at odds 2.3 and autonomic neuropathy at odds 4.9, along with eye and kidney complications. The fascia thickened before the neuropathy arrived.
Study notesProspective cohort.
Who and what was studiedTwenty-two patients with diabetes at high risk of diabetic foot and 22 healthy volunteers, MRI of the plantar fascia, tendons and foot muscles.
What it foundEighty-six percent of the diabetic patients had an irregular plantar fascia against none of the controls, and the fascia was larger in those without arterial disease.
Study notesSmall MRI comparison.
MRI puts the inflammation of PMR in the connective tissue sheaths around the tendons and capsules rather than inside the joints, so clearly that counting inflamed connective tissue sites can diagnose it.
Who and what was studiedEighteen patients with active, recent-onset polymyalgia rheumatica, MRI of the shoulder and pelvic girdles at baseline and after two and twelve weeks of treatment.
What it foundEvery patient had at least one inflammatory myofascial lesion at baseline, 71 percent at the shoulder, 87 percent at the hip and 80 percent at the pubic symphysis, identified reproducibly by blinded radiologists and improving on treatment.
Study notesPost-hoc analysis of a treatment trial.
Who and what was studiedForty contrast-enhanced pelvic MRIs of polymyalgia rheumatica patients scored by a musculoskeletal radiologist.
What it foundEvery patient had inflammation on both sides in the connective tissue sheaths around the pelvic girdle tendons, at four or more sites each, which the authors call the hallmark of the disease. The inflammation sits in the sheath around the tendon, not in the joint.
Study notesDescriptive imaging series.
Who and what was studiedOne hundred and twenty patients with pelvic girdle pain, 40 with polymyalgia rheumatica and 80 controls, scored by three blinded radiologists at 19 predefined sites.
What it foundPatients had inflammation at 13.4 sites against 4.0 in controls, and a cut-off of ten or more inflamed connective tissue sites identified the disease at 95.8 percent sensitivity. The diagnostic pattern is extracapsular, in the sheaths around tendons and capsules.
Study notesDiagnostic accuracy study.
Who and what was studiedTwenty-five patients with polymyalgia rheumatica or giant cell arteritis and 25 matched controls, imaged by PET/CT at the knees.
What it foundEighty-four percent showed inflammation at both knees, with the tracer outlining the fibrous capsule: 90 percent of capsular connective tissue sites were inflamed against 23 percent of sites inside the joint.
Study notesCross-sectional imaging.
The Lyme bacterium settles in connective tissue and survives there. Musculoskeletal pain that runs for years after the antibiotics fits changed tissue rather than an infection still going.
Who and what was studiedFive studies covering 504 people who had had Lyme disease and 530 controls.
What it foundFatigue, musculoskeletal pain and cognitive trouble were significantly more common after Lyme disease, on 8 of 10 symptoms, and the authors judge the evidence strong that these can run for years despite antibiotics. Pain that outlasts a cleared infection points to changed tissue.
Study notesPooled analysis.
Who and what was studiedChronically infected mice, with the Lyme bacterium tracked against connective tissue components.
What it foundThe organism settles by preference in the extracellular matrix of connective tissue, sitting exactly with the proteoglycan decorin, and survived there after antibody treatment had cleared other sites, then repopulated from it. Decorin belongs to the collagen matrix of fascia.
Study notesAnimal study.
Who and what was studiedConnective tissue taken at surgery from a woman whose chronic Lyme disease had progressed despite antibiotics.
What it foundLive spirochetes were cultured from the ligamentous tissue, and electron microscopy showed them lying between the collagen fibres and along the fibroblasts. Direct human evidence of persistence inside dense connective tissue after treatment.
Study notesSingle case.
Nearly a third of people meet fibromyalgia criteria six months after COVID-19. Biopsies show why: thicker connective tissue around the smallest vessels, and fibrosis in the tissue of people who were never hospitalised.
Who and what was studiedA hypothesis and theory paper.
What it foundNotes that 30 to 40 percent of people recovering from COVID-19 go on to chronic widespread pain and fatigue and meet 2016 fibromyalgia criteria, and extends the contractile myofibroblast and matrix remodelling model of fascia to long COVID's pain, fatigue and autonomic features.
Study notesTheory paper.
Who and what was studiedSix hundred and sixteen people surveyed roughly six months after COVID-19 against ACR fibromyalgia survey criteria.
What it foundThirty point seven percent met criteria for fibromyalgia six months on. Widespread musculoskeletal pain and stiffness is among the commonest outcomes of the infection, and fibromyalgia is where fascial inflammation and stiffness have been proposed as the pain source.
Study notesWeb-based survey.
Who and what was studiedMuscle biopsies from 11 patients with lasting fatigue and post-exertional malaise after COVID-19 against two historical control cohorts.
What it foundPatients had fewer capillaries, thicker capillary basement membranes and more macrophages, with no virus detectable, which the authors read as lasting structural change in the microvasculature. Thicker connective tissue around the smallest vessels means less water and fewer nutrients reaching the tissue.
Study notesSmall biopsy series.
Who and what was studiedMuscle biopsies from 28 non-hospitalised post-COVID patients and 28 matched healthy controls.
What it foundEighty-one percent of the post-COVID group had tissue fibrosis, alongside abnormally shaped and smaller fibres and fewer nuclei per fibre, so structural change is present even in people never admitted to hospital.
Study notesBiopsy case-control study.
Who and what was studiedA longitudinal case-control study with muscle biopsies before and after an exercise challenge in long COVID patients.
What it foundTissue structure tracked lower exercise capacity, and severe exercise-induced damage with amyloid-containing deposits got worse once post-exertional malaise was provoked. Damage that deepens after exertion is the physical basis of the crash.
Study notesRegistered clinical study.
Who and what was studiedThirty-three studies covering 14,639 hospitalised and 11,070 non-hospitalised COVID-19 patients, pooled by follow-up point.
What it foundMusculoskeletal pain ran through the whole first year after infection, with pooled muscle pain reaching 18 percent and joint pain 12 percent at various follow-up points.
Study notesThe studies pooled here vary widely.
Who and what was studiedSixty-four observational studies of musculoskeletal symptoms after COVID-19.
What it foundPooled muscle pain came out at 28 percent and was still 25.9 percent at twelve months, with joint pain at 14.8 percent and weakness at 12.9 percent. Muscle pain, which lives in myofascial tissue, is the commonest musculoskeletal outcome.
Study notesHigh heterogeneity.
Who and what was studiedA chart review of pain clinic patients whose myofascial pain syndrome began or worsened after COVID-19.
What it foundPatients developed new or worse myofascial pain with trigger points after the infection, and the authors propose a relationship between the two, describing the syndrome as chronic muscle pain involving the connective tissue inside the muscles.
Study notesSmall case series.
Recent tissue studies show structural change in peripheral tissue that inactivity cannot account for, driven by poor perfusion, which is the same shortfall in supply that leaves fascia short of water.
Who and what was studiedA review of the tissue-level evidence in ME/CFS and post-COVID ME/CFS.
What it foundFinds strong recent evidence for muscle-tissue pathology, electron microscopy included, and explains the condition through poor perfusion and ischaemia of peripheral tissue rather than a purely central process. That shortfall in supply is the same one that leaves fascia short of water and nutrients.
Study notesNarrative review.
Who and what was studiedLong COVID and ME/CFS patients against healthy people before and after 60 days of strict bed rest, with exercise testing and muscle biopsies.
What it foundThe tissue changes in patients were different from those inactivity produces, so deconditioning cannot account for them. Both groups carried more glycolytic fibres and ME/CFS patients showed a specific fibre atrophy. Biopsies include the fascia threaded through the muscle.
Study notesBed-rest comparison study.
Half of people with relapsing-remitting MS have myofascial pain syndrome, and treating the myofascial tissue directly cut both pain and fatigue.
Who and what was studiedOne hundred and thirty-seven relapsing-remitting MS patients screened for myofascial pain syndrome, 25 of them treated with trigger point injections and followed.
What it foundMyofascial pain syndrome was present in 51.9 percent, and treating the myofascial tissue directly with anaesthetic injections significantly cut pain and fatigue and lifted quality of life at three months.
Study notesThe treatment arm was open-label.
The hyaluronan model of stiffness has its clearest human evidence here. Imaging shows more hyaluronan in stiff muscle, and clearing it with an enzyme gives the movement back.
Who and what was studiedFive patients with post-stroke muscle stiffness and 5 healthy controls, hyaluronan mapped by T1ρ MRI in the upper arm before and after hyaluronidase injections.
What it foundHyaluronan was significantly higher in the stiff biceps than in controls, 34.04 against 26.70 ms, and fell once the enzyme that breaks it down was injected. Direct human imaging evidence that hyaluronan builds up in stiff tissue and that clearing it restores movement.
Study notesSmall pilot study.
More than 70 percent of women develop musculoskeletal pain and stiffness through menopause. Fascia answers to oestrogen directly: its cells carry the receptors, and oestrogen sets the collagen content of connective tissue.
Who and what was studiedA review that names the collective musculoskeletal effects of losing oestrogen.
What it foundMore than 70 percent of women get musculoskeletal symptoms through the menopause transition and 25 percent are disabled by them, joint pain and stiffness included, largely on oestrogen loss. Fascial cells carry oestrogen receptors, and oestrogen loss changes connective tissue collagen.
Study notesNarrative review.
Who and what was studiedA review of oestrogen and connective tissue.
What it foundConnective tissue collagen loss tracks oestrogen deficiency at menopause closely, oestrogen has deep effects on connective tissue turnover at every site, and taking it after menopause raises collagen content, thickness and elasticity. Fascia is that same tissue.
Study notesNarrative review.
Who and what was studiedA review of oestrogen's effects on muscle, tendon and ligament.
What it foundOestrogen reaches well past bone: it raises the collagen content of connective tissue and directly sets the stiffness of tendons and ligaments, so losing it changes the tissue. Fascia is the same collagen-based tissue answering the same hormone.
Study notesNarrative review.
Who and what was studiedA review of sex hormone effects on tendon and ligament collagen.
What it foundOestrogen lifts tendon collagen synthesis and shapes fibre cross-linking and joint laxity, and very low levels leave connective tissue worse placed under load and in recovery. The collagen synthesis that keeps tendon healthy keeps fascia healthy.
Study notesNarrative review.
Fascia is one of the more densely nerved soft tissues around a joint, which researchers put forward as a reason pain can persist after surgery when the joint itself looks fine.
Alongside the conditions above, a growing number of researchers are putting fascial densification forward as a thread running through problems still treated as separate. The work is early, the mechanism is the same one described in Part A, and the imaging that could settle it exists now.
Fascial Release is a nine-ingredient formula built around the mechanism above. This part sets out how the formula is organised, then lists the published research behind every ingredient in it, labelled the same way as Part A.
Healthy fascia stays soft and supple because water and nutrients keep reaching it. When that supply runs short the tissue dries out, thickens and begins to squeeze the muscles and nerves passing through it. Fascial Release was designed backwards from that sequence. Every ingredient in it has one of four jobs, and the research below is what has been published on each one for connective tissue hydration, collagen, soft-tissue swelling, inflammation, and pain and stiffness.
Put back the hyaluronic acid and the nutrients fascia needs in order to hold water. High-molecular-weight hyaluronic acid, paired with pine bark extract, which pushes the body to make more of its own.
Fascia holds its water inside a lattice of collagen and proteoglycans. Silica, manganese, boron, grape seed extract and gotu kola supply the raw material that lattice is built and repaired from.
Clear the protein build-up that keeps thickened fascia clamped down. Serrapeptase, a proteolytic enzyme with trial evidence behind it for bringing soft-tissue swelling down.
Low-grade inflammation thickens the fluid between fascial layers and leaves the nerve endings inside them touchy. Boswellia, boron, grape seed extract and gotu kola carry the inflammatory-marker and pain-and-stiffness evidence.
One row per ingredient: the job it does in the formula, what the published research found, and what kind of evidence that is. The number takes you to the studies.
| Ingredient | What it does in the formula | What the research found | Type of evidence | Studies |
|---|---|---|---|---|
| Hyaluronic acid | Rehydrates the fascia | Less pain and stiffness in 9 of the 11 trials reviewed, better knee comfort in adults with no arthritis, more water held in connective tissue | Systematic review and randomised trials | 8 |
| Pine bark extract | Rehydrates the fascia and calms inflammation | Joint symptom scores down 56 percent and walking distance tripled in a placebo-controlled trial, lower CRP, more of the body's own hyaluronic acid synthase | Randomised trials | 4 |
| Grape seed extract | Feeds the fascia's structure and calms inflammation | Lower hs-CRP across pooled trials, less fluid retention and swelling, collagen and elastin protected | Meta-analyses and randomised trials | 4 |
| Bamboo extract (silica) | Feeds the fascia's structure | Firmer, better-hydrated connective tissue in placebo-controlled trials of bioavailable silicon, which the cross-links holding collagen and proteoglycans together depend on | Randomised trials and reviews | 5 |
| Manganese | Feeds the fascia's structure | Required by the enzymes that build proteoglycans and recycle collagen, and part of two placebo-controlled knee trials | Mechanistic studies and combination trials | 4 |
| Boron | Calms inflammation | Less knee discomfort inside 14 days in a placebo-controlled trial, lower hs-CRP and TNF-α | Randomised trials | 4 |
| Serrapeptase | Releases densified tissue | Less soft-tissue swelling and stiffness after surgery in a randomised trial, and swelling down faster than paracetamol after injury | Randomised and comparative trials | 4 |
| Boswellia serrata | Calms inflammation | Significantly less pain and stiffness across pooled trials, improvement inside five days, lower TNF-α, hs-CRP and IL-6 | Two meta-analyses and several randomised trials | 6 |
| Gotu kola (Centella asiatica) | Feeds the fascia's structure and calms inflammation | Drives collagen I production, lower IL-1β, IL-6 and TNF-α, less swelling and capillary leakage in placebo-controlled trials | Systematic review and randomised trials | 6 |
One block per ingredient, each with its role in the formula and its own study list, labelled the same way as Part A. Where a trial was paid for by the maker of the ingredient it tested, the notes say so.
RoleRehydrates the fascia
Who and what was studiedEleven articles covering 597 patients on oral hyaluronic acid in rheumatic conditions between 1966 and May 2024, ten in osteoarthritis and one in low back pain, followed from four weeks to twelve months.
What it foundNine of the eleven reported improvement on pain, WOMAC, joint function, Lequesne index or stiffness, and the two that measured cytokines found them lower afterwards. Side effects were rare and mild. Hyaluronic acid is what keeps the fluid between fascial layers thin enough to move.
Study notesQualitative synthesis with no pooled effect size, and the trials used several branded products.
Who and what was studiedHealthy adults around 60 with knee discomfort but no diagnosed osteoarthritis, over 12 weeks, on visual analogue scales with mobility and leg-strength tests.
What it foundTotal scores for pain, stiffness and discomfort were significantly lower than placebo across the 12 weeks, while mobility tests and blood markers did not differ. A benefit in people with no joint damage points at the connective tissue around the joint rather than cartilage.
Study notesWritten by researchers at a hyaluronic acid producer.
Who and what was studiedSixty adults with symptomatic knee osteoarthritis over eight weeks, measured on WOMAC, Lequesne index, pain, rescue medication and range of motion.
What it foundPain, total WOMAC, Lequesne index and range of motion all improved significantly from baseline, and at 60 days pain and WOMAC pain were significantly below placebo, with weekly rescue medication down. Movement improved faster than cartilage can change.
Study notesPilot study.
Who and what was studiedA rat osteoarthritis model comparing hyaluronic acid at different molecular weights, followed by a human trial of the form chosen.
What it foundIn rats, oral hyaluronic acid cut joint swelling, raised hyaluronic acid in serum and synovial fluid and lowered pro-inflammatory cytokines, MMPs, iNOS and COX-2, most strongly at high molecular weight. The human arm significantly improved WOMAC pain, stiffness and function with clean safety markers.
Study notesWritten by researchers at a hyaluronic acid producer, and the human arm is a pilot.
Who and what was studiedA review of randomised, double-blind, placebo-controlled trials of oral hyaluronan for knee pain from 2008 to 2015, with mechanism and safety.
What it foundConcludes the trials support oral hyaluronan for symptoms tied to synovitis, particularly knee pain, effusion and inflammation, and muscular knee strength, and sets out the proposed route through receptor binding in the intestinal lining.
Study notesReview written by researchers at a hyaluronic acid producer.
Who and what was studiedSixty-one subjects with dry skin given oral hyaluronan at two molecular weights or placebo for six weeks, with skin moisture measured.
What it foundMoisture rose more in both hyaluronan groups than placebo, and the 300k group was still significantly better two weeks after stopping, with no adverse events on dermatologist review. Skin is connective tissue continuous with the superficial fascia beneath it.
Study notesSkin was measured here, not fascia.
Who and what was studiedA review of how ingested hyaluronan is absorbed, distributed and acts.
What it foundGathers the evidence that ingested hyaluronan is absorbed, reaches the skin in part, adds to the body's own hyaluronan synthesis and encourages fibroblasts to multiply, and that in a placebo-controlled trial it raised skin moisture in dry skin.
Study notesReview, and the distribution evidence is partly from animal work.
Who and what was studiedSixty-six randomised controlled trials of oral supplements for skin moisturising between 2000 and 2021, pooled where four or more trials existed.
What it foundBoth hyaluronan and procyanidin, the proanthocyanidin class found in pine bark and grape seed, showed a statistically significant positive effect on skin hydration, with too few trials to judge water loss.
Study notesSkin hydration stands in for connective tissue hydration.
RoleRehydrates the fascia and calms inflammation
Who and what was studiedOne hundred and fifty-six osteoarthritis patients, 77 on pine bark extract and 79 on placebo for three months, measured on WOMAC, treadmill distance, medication use and foot oedema.
What it foundGlobal WOMAC fell 56 percent against 9.6 percent on placebo, treadmill distance went from 68 m to 198 m against 65 m to 88 m, pain medication use fell 58 percent, and foot oedema improved in 79 percent of treated patients against 1 percent of controls. That oedema is fluid held in connective tissue.
Study notesSponsored by the extract's manufacturer.
Who and what was studiedOne hundred patients with stage I to II knee osteoarthritis on pine bark extract or placebo for three months, WOMAC every fortnight and pain weekly.
What it foundWOMAC improved and pain fell significantly on pine bark with nothing from placebo, and painkiller use dropped on the extract while rising on placebo. Improvement in mild disease, before major joint damage, points at the tissue around the joint.
Study notesSponsored by the extract's manufacturer.
Who and what was studiedThe subset of the same trial with raised C-reactive protein at baseline, 29 on pine bark extract and 26 on placebo over three months.
What it foundCRP fell from 3.9 to 1.1 mg/L on pine bark against 3.9 to 3.6 on placebo, plasma free radicals dropped to 70.1 percent of baseline and fibrinogen to 62.8 percent. CRP is the systemic marker of the low-grade inflammation that keeps fascia tight.
Study notesSubgroup analysis of the trial above.
Who and what was studiedTwenty healthy postmenopausal women supplemented for 12 weeks, skin measured by corneometry, cutometry and ultrasound with biopsies for gene expression.
What it foundHydration and elasticity improved significantly, most in the women who started dry, alongside a significant rise in hyaluronic acid synthase-1 and collagen type I gene expression. That enzyme is the one fascial cells use to make their own hyaluronic acid.
Study notesOpen-label study in 20 women.
RoleFeeds the fascia's structure and calms inflammation
Who and what was studiedTwenty-three studies reviewed and 19 pooled, covering markers of oxidative stress and inflammation.
What it foundGrape seed extract significantly lowered malondialdehyde (SMD -1.04), oxidised LDL (SMD -0.44) and high-sensitivity CRP (-0.48 mg/L). Low-grade inflammation on hs-CRP is what keeps hyaluronan clumped and fascia densified.
Study notesThe trial populations were mostly cardiometabolic.
Who and what was studiedSeventeen randomised trials and 668 participants on grape products, grape seed extract among them.
What it foundGrape polyphenols significantly lowered CRP overall (SMD -0.229), with bigger effects at higher doses, in trials of twelve weeks or more, and in people with a clinical condition.
Study notesPools several grape products rather than grape seed alone.
Who and what was studiedHealthy Japanese women in double-blind placebo-controlled crossover trials of a single dose and 14 days of dosing, followed by six hours of sitting.
What it foundLeg volume distension, the rise in extracellular fluid and leg water were all significantly held down against placebo. Leg swelling is fluid retained in the superficial fascia and the connective tissue around it.
Study notesHealthy women, and it measures fluid retention rather than pain.
Who and what was studiedA narrative review of proanthocyanidins, the polyphenol class in grape seed and pine bark.
What it foundReviews the evidence that they cut oxidative stress, push collagen and elastin synthesis and damp inflammatory signalling in ageing skin, while flagging low bioavailability and instability as limits. Collagen and elastin are the framework fascia holds its water inside.
Study notesMostly cell and animal data.
RoleFeeds the fascia's structure
Who and what was studiedFifty women with photodamaged facial skin randomised to a bioavailable silicon supplement or placebo for 20 weeks, with skin microrelief, hydration and mechanical properties measured.
What it foundSerum silicon rose on supplementation. Roughness worsened by 6 to 11 percent on placebo but improved by 8 to 19 percent on silicon, a significant difference, and mechanical anisotropy improved. The authors propose a role for silicon in forming and maintaining connective tissue.
Study notesUses orthosilicic acid rather than bamboo silica, and measures skin rather than fascia.
Who and what was studiedTwenty-two patients randomised to a stabilised orthosilicic acid supplement or placebo for 90 days.
What it foundTexture, firmness and hydration came out statistically better on silicon, with 80 percent treatment satisfaction and no side effects. Firmer, better-hydrated skin means a better-kept connective tissue framework.
Study notesSmall trial, and the silicon was combined with collagen.
Who and what was studiedA narrative review of eight human studies covering more than 10,000 subjects on silicon intake and supplementation.
What it foundReports that lab and animal work ties silicon to glycosaminoglycans and gives it an important part in forming the cross-links between collagen and proteoglycans. Those cross-links are what let fascia hold water inside its framework.
Study notesBone-focused, with the connective tissue mechanism coming from lab and animal data.
Who and what was studiedAn umbrella review of controlled animal studies of silicon and bone.
What it foundSets out the intake levels that affect bone and mineral metabolism across species, and the association between silicon and the organic collagen matrix of bone and connective tissue.
Study notesAnimal data, and the scope is bone.
Who and what was studiedA review of silicon metabolism and its role in bone and connective tissue.
What it foundConcludes that thirty years of accumulating evidence points to dietary silicon benefiting bone and connective tissue, with synthesis and stabilisation of collagen among the proposed mechanisms.
Study notesReview, and the mechanisms are described as not yet settled.
RoleFeeds the fascia's structure
Who and what was studiedBiochemical characterisation of recombinant human prolidase.
What it foundProlidase, the enzyme that recovers proline and hydroxyproline from broken-down collagen so new collagen can be built, is manganese-dependent, and manganese with glutathione improved both its activity and its stability. Fascia's collagen is recycled constantly.
Study notesEnzyme biochemistry.
Who and what was studiedProteoglycans extracted from the growth-plate cartilage of manganese-deficient and normal chicks.
What it foundManganese deficiency cut total cartilage proteoglycans and left a quarter of the remaining monomers abnormal with less carbohydrate. Proteoglycans are the water-binding molecules of connective tissue, fascia included.
Study notesAnimal study.
Who and what was studiedNinety-three knee osteoarthritis patients randomised to a glucosamine, chondroitin and manganese ascorbate combination or placebo for six months.
What it foundPatients with mild or moderate disease on X-ray improved significantly on the Lequesne index at four and six months, with a 52 percent response rate against 28 percent on placebo. Severe disease did not improve significantly.
Study notesA combination product, so manganese's own share cannot be separated out.
Who and what was studiedThirty-four US Navy men with chronic pain and degenerative joint disease of the knee or low back, in a 16-week crossover trial.
What it foundKnee symptoms eased on the combination, with the summary disease score down 16.3 percent, clinic pain down 26.6 percent and the physical examination score down 43.3 percent. A spinal benefit was neither shown nor ruled out.
Study notesA combination product, and a small pilot.
RoleCalms inflammation
Who and what was studiedSixty participants with self-reported knee discomfort randomised to calcium fructoborate, a plant-form boron complex, or placebo, scored on WOMAC and the McGill Pain Questionnaire at 7 and 14 days.
What it foundAgainst placebo the McGill difference was -5.8 at day 7 and -8.9 at day 14, and WOMAC -5.3 then -13.73, while the placebo group did not move. Relief inside two weeks is quicker than joint structure can change.
Study notesA two-week trial sponsored by the ingredient's manufacturer.
Who and what was studiedSixty completers with knee osteoarthritis in a 15-day placebo-controlled trial measuring CRP, fibrinogen, ESR and lipids.
What it foundCalcium fructoborate improved inflammatory markers across all treated groups against placebo, with slight lipid changes and no serious adverse events. CRP and fibrinogen mark the low-grade inflammation that keeps fascia tight.
Study notesA two-week pilot.
Who and what was studiedEight healthy men, blood sampled over six hours after one boron dose and again after a week of daily supplementation.
What it foundPlasma boron rose quickly, and six hours in there was a significant fall in high-sensitivity CRP and TNF-α, with further hormone changes after a week. Those are the signals that thicken the fluid between fascial layers.
Study notesEight subjects, short duration.
Who and what was studiedA narrative review.
What it foundGathers the human evidence that boron matters for bone growth and upkeep, wound healing, the body's handling of oestrogen, testosterone, vitamin D and magnesium, and for lowering inflammatory markers including hs-CRP and TNF-α, while raising antioxidant enzymes.
Study notesNarrative review.
RoleReleases densified tissue
Who and what was studiedOne hundred and thirty-three patients after surgical removal of an impacted lower third molar, randomised to serratiopeptidase with paracetamol or placebo with paracetamol for five days.
What it foundSerratiopeptidase significantly improved jaw opening on day 4 and cut swelling, while reported pain did not differ between groups. Post-surgical swelling and stiffness is fluid and protein debris collecting in soft connective tissue, and it cleared faster.
Study notesMeasures acute post-surgical swelling across five days.
Who and what was studiedSeventy-six patients aged 18 to 53 with a grade II ankle sprain, put on serrapeptase or paracetamol for ten days, with oedema measured two ways and pain on a visual scale.
What it foundSerrapeptase reduced ankle oedema better than paracetamol at both day 3 and day 10, while pain did not differ significantly. The swelling after a sprain sits in the fascia and connective tissue around the joint.
Study notesNot randomised, and compared against paracetamol rather than placebo.
Who and what was studiedA review of the enzyme's properties, uses, production and analysis.
What it foundDescribes serratiopeptidase as a widely used anti-inflammatory enzyme and an alternative to NSAIDs, with established use for post-operative swelling and proposed use in arthritis. A proteolytic enzyme breaks down the inflammatory protein and fibrin debris that keeps densified tissue compressed.
Study notesNarrative review.
Who and what was studiedA narrative review.
What it foundSets out serratiopeptidase as a proteolytic enzyme with anti-inflammatory, anti-oedemic and fibrinolytic action and an affinity for cyclooxygenase, while noting how thin the research base is next to conventional drugs.
Study notesNarrative review.
RoleCalms inflammation
Who and what was studiedSeven randomised trials and 545 osteoarthritis patients, Boswellia or its extract against placebo or conventional medicine.
What it foundAgainst control, Boswellia cut pain (VAS -8.33, WOMAC pain -14.22) and stiffness (WOMAC stiffness -10.04) and improved function (WOMAC function -10.75, Lequesne -2.27), with the authors recommending at least four weeks of use. Stiffness is a fascial symptom, and the effect on it is as clear as the effect on pain.
Study notesHigh heterogeneity, and few trials.
Who and what was studiedThirteen randomised controlled studies in knee osteoarthritis, 850 patients with WOMAC data and 1,185 with pain-scale data.
What it foundThe largest pooled analysis for Boswellia in knee osteoarthritis. Against placebo the extracts produced significantly lower WOMAC scores, confirmed on meta-regression, which the authors flag as useful for people who cannot take NSAIDs.
Study notesThe pooled result across all comparators, not placebo alone, was limited by heterogeneity.
Who and what was studiedOne hundred and five newly diagnosed knee osteoarthritis patients randomised to placebo or two doses of an AKBA-standardised extract for 90 days, with inflammatory markers at five time points.
What it foundPain improved from day 5. By day 90 pain was down 45.3 and 61.9 percent at the two doses, WOMAC total up 68.5 and 73.6 percent and WOMAC stiffness up 65.6 and 68.9 percent, with serum TNF-α, hs-CRP and IL-6 all falling. Those are the signals that drive hyaluronan to clump.
Study notesSponsored by the extract's manufacturer.
Who and what was studiedSeventy-five knee osteoarthritis patients randomised to two doses of an AKBA-enriched extract or placebo for 90 days, with MMP-3 measured in synovial fluid.
What it foundBoth doses gave clinically and statistically significant gains in pain and function by the end, as early as day 7 on the higher dose, alongside less MMP-3 in synovial fluid. MMP-3 is one of the enzymes that degrades the connective tissue matrix.
Study notesSponsored by the extract's manufacturer.
Who and what was studiedSixty knee osteoarthritis patients randomised to a Boswellia-derived composition or placebo for 30 days, assessed at days 5, 15 and 30.
What it foundClinically and statistically significant gains in pain and function, with significant improvement as early as five days. Relief that fast is quicker than structural joint change and points at inflammation in the soft tissue around the joint.
Study notesSponsored by the extract's manufacturer, over 30 days.
Who and what was studiedThirty knee osteoarthritis patients in a crossover design, eight weeks per phase.
What it foundEvery patient on the extract reported less knee pain, more flexion and further walking, with swelling becoming less frequent, all significantly different from placebo and described as clinically relevant. X-rays did not change.
Study notesSmall early trial.
RoleFeeds the fascia's structure and calms inflammation
Who and what was studiedFour clinical trials of Centella asiatica in wound healing, reviewed under PRISMA.
What it foundConcludes it may improve wound healing through better angiogenesis, driven by its push on collagen I, fibroblast growth factor and VEGF, with an anti-inflammatory effect showing as lower IL-1β, IL-6, TNF-α, PGE2 and COX-2. Collagen I and lower cytokines are what a densified fascia needs.
Study notesFour trials, mostly topical use.
Who and what was studiedFifty-two patients with venous hypertension randomised to two doses of oral Centella triterpenes or placebo for four weeks, plus 10 normal subjects.
What it foundAfter four weeks capillary filtration rate, ankle circumference and ankle oedema all fell significantly in treated patients and more so at the higher dose, with nothing on placebo. Capillary leakage and oedema are fluid collecting in superficial fascia.
Study notesOral Centella, but venous oedema rather than a pain condition.
Who and what was studiedA single-blind, placebo-controlled, randomised study of two doses of oral Centella triterpenes in venous hypertensive microangiopathy.
What it foundObjective microcirculation tests, laser Doppler and transcutaneous oxygen and carbon dioxide, improved significantly on treatment with nothing on placebo, and symptom scores moved with them, especially at the higher dose. Better microcirculation means more water and nutrients reaching the tissue.
Study notesAn older trial, single-blind.
Who and what was studiedPassengers aged 30 to 50 with mild to moderate venous disease on flights over three hours, randomised to oral Centella triterpenes or no treatment.
What it foundAnkle swelling rate and oedema were significantly lower in the treated group, and the microcirculation changes that come with flight time were milder.
Study notesNo placebo; the control group was untreated.
Who and what was studiedA review of the two marker triterpenoid glycosides of Centella asiatica.
What it foundReports wound healing, anti-inflammatory, antioxidant, antifibrotic and anti-arthritic activity for asiaticoside and madecassoside, mostly from preclinical work, alongside their established use in skin and scar conditions.
Study notesLittle human data.
Who and what was studiedA review of the mechanisms and clinical trials of topical Centella.
What it foundSets out how asiaticoside, madecassoside, asiatic acid and madecassic acid lift collagen synthesis, modulate inflammation and give antioxidant protection. The same compounds act on the connective tissue fascia is made of.
Study notesTopical use only.
Nothing matches those filters. Clear them, or try a different word.
The research on this page is real and most of it is recent. The anatomy of fascia and the nerve supply inside it are settled science. Densification has a clear mechanism, a growing set of imaging studies able to measure it, and treatment studies showing that working on fascia brings pain down. Fascia is now a named target in pain research, and the 2025 scoping review in Part A puts chronic pain at the front of where the field is going. Every ingredient in Fascial Release has published research behind the job it does, from pooled trials on Boswellia and hyaluronic acid through to placebo-controlled trials on pine bark, boron, serrapeptase and silicon.
Almost every study here was published inside the last ten years, and the imaging work is mostly from the last five. That is the reason so many people are hearing about fascia for the first time. This page is updated whenever new work publishes.
Every study cited here was independently published, peer reviewed and is publicly verifiable. Fascial did not fund, design or run any of the research on this page. Where a trial was paid for by the maker of the ingredient it tested, the entry says so. A study appearing here is not a claim that Fascial Release itself was tested in it, and nothing on this page is medical advice. Fascial Release is a food supplement and is not intended to diagnose, treat, cure or prevent any disease. Speak to your doctor before starting any supplement, particularly if you are pregnant, breastfeeding, taking prescription medicines or living with a diagnosed condition.
